Drug Trial Radar · NCT00859872
Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia
Last checked: Nov 20, 2026Latest source record: Aug 3, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
198
Actual
Start
Aug 2008
Primary completion
Mar 2009
Study completion Mar 2009
Sponsor
- Lead sponsor
- Central South UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Wuhan Mental Health Centre; Capital Medical University; Shanghai Mental Health Center; Guangzhou Mental Hospital; Chongqing Mental Hospital
- First posted
- Mar 11, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-centre, open, randomized, haloperidol-referenced, 47 days two treatment sessions, parallel-group study. After screening period, eligible subjects will be entered 5 days treatment session I to compare the efficacy between risperidone oral solution combination clonazepam oral and haloperidol IM injection on controlling psychotic agitation, then will be followed by 6 additional weeks treatment session II for exploring the effect of medicine switching from IM injection to oral.
Conditions
- Schizophrenia
Interventions
risperidone oral solutionDrug
risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
haloperidolDrug
haloperidol IM injection (5-20mg/d)
Primary outcomes
What the sponsor says the trial is designed to measure.
- the change of PANSS-EC scoresTime frame: 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MentalHealth Institute of the 2nd Xiangya Hospital, Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.